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MISCELLANEOUS TOPICS 
Magnitude and Implications of Spontaneous Hemodynamic 
Variability in Primary Pulmonary Hypertension 
STUART RICH, MD, GILBERT E. D’ALONZO, DO, DAVID R. DANTZKER, MD, 
and PAUL S. LEVY, ScD 
The pulmonary artery (PA) pressure and pulmonary 
resistance at rest have been noted to vary sponta- 
neously in patients with primary pulmonary hyper- 
tension. To evaluate this variation, in 12 patients (8 
women, 4 men, aged 43 f 13 years), hourly mea- 
surements were made for 6 consecutive hours of 
heart rate, systemic and PA pressures, cardiac 
output, systemic and pulmonary resistance. After 
these baseline measurements the patients were 
tested with hydralazine and nifedipine therapy. 
Spontaneous variability in pulmonary pressures and 
resistances occurred in each patient, with the 
amount of variation (coefficient of variation) in PA 
pressure averaging 8% and in total pulmonary re- 
sistance 13 % over the 6 hours. The patients with the 
most variability in mean PA pressure also had the 
most variability in cardiac output (r = 0.69, p = 
0.02). Variability also correlated with the severity 
of the disease, as the patients with the highest total 
pulmonary resistances also had the most variation 
for that factor (r = 0.91, p <O.Ol). The amount of 
variability did not correlate, however, with the acute 
response to either hydralazine or nifedipine ad- 
ministration. Based on the average coefficients of 
variation in these 12 patients, estimates were ob- 
tained of the percent change needed for an observed 
change to be attributed to a drug effect with 95% 
confidence. From these estimates, it was projected 
that for a single patient, a mean change in pulmo- 
nary resistance of 36% or a mean change in PA 
pressure of 22% would be required in order to at- 
tribute the changes to a drug effect. Thus, sponta- 
neous hemodynamic variability is a common phe- 
nomenon in patients with primary pulmonary 
hypertension and may account for substantial 
changes in PA pressure and pulmonary resistance 
at rest. 
(Am J Cardiol 1985;55:159-163) 
Vasodilator drugs have been reported to lower the 
pulmonary artery (PA) pressure and pulmonary vas- 
cular resistance in patients with primary pulmonary 
hypertension (PPH).1-5 However, PA pressure and 
pulmonary resistance may change spontaneously, 
without any drug intervention.6 The implications of this 
spontaneous variability are not clear, nor is it known if 
it is a common or unusual phenomenon. We monitored 
the pulmonary and systemic central hemodynamics of 
12 patients with PPH every hour for 6 consecutive hours 
to determine their magnitude of variation. We then 
administered vasodilator drugs to these patients and 
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noted if there was any relation between the magnitude 
of hemodynamic variability and drug responsiveness. 
Methods 
Subjects: The study includes 12 consecutive patients (8 
women, 4 men) referred to the University of Illinois and 
University of Michigan Hospitals over a l-year period for 
evaluation of PPH. They were aged 23 to 60 years old (mean 
43 f 13). Each underwent an extensive work-up to determine 
the cause of the pulmonary hypertension, but no cause was 
found.7 Each patient was admitted to have hemodynamic 
testing for evaluation of vasodilator therapy while receiving 
no vasodilator drugs with the exception of digoxin and diuretic 
therapy. 
Hemodynamic monitoring: A Swan-Ganz catheter was 
directed into the PA, and a small radial artery cannula was 
placed for hemodynamic monitoring. Each patient was 
monitored for at least 6 consecutive hours in an intensive care 
unit, and values were recorded every hour. Heart rate, systolic, 
diastolic and mean systemic and PA pressures, pulmonary 
wedge pressure, and right atria1 pressure were recorded. 
Cardiac output was determined by the thermodilution tech- 
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TABLE I Hemodynamic Characteristics of the Patients Studied 
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All patient data represent the mean of the 6 consecutive hourly determinations. 
CO = cardiac output; HR = heart rate; PAP = mean pulmonary artery pressure; SAP = mean systemic 
arterial pressure; SV = stroke volume; TPR = total pulmonary resistance; TSR = total systemic resis- 
nique. Systemic and pulmonary resistances were calculated 
in Wood units from standard formulas. 
In each case the serial hemodynamic measurements were 
made with the patient supine and at rest. Although not the 
same person made these measurements in all patients, the 
same person made all of the measurements for any given pa- 
tient over the B-hour monitoring period. All measurements 
were made during the daytime and evening hours. The re- 
producibility and reliability of the thermodilution technique 
were assessed at both institutions, with simultaneous ther- 
modilution and Fick cardiac output determinations made on 
a different group of subjects. The correlation between these 
techniques was highly significant (r = 0.81, p <O.OOl at the 
University of Illinois; r = 0.96, p <O.OOl at the University of 
Michigan). 
Drug testing: After the 6-hour baseline period was estab- 
lished, 8 patients were administered hydralaxine and 10 were 
given nifedipine. Hydralazine was administered as a 0.3~mglkg 
slow intravenous infusion or a SO-mg oral dose, with mea- 
surements made after 30 minutes and 2 hours, respectively. 
Nifedipine was administered as either a lo- or 20-mg oral dose, 
and the measurements made after 90 to 120 minutes. A new 
control state was established before each drug test. 
Data management and statistical methods: For each 
patient the mean level of each of the 7 hemodynamic variables 
over the 6 time intervals was computed along with the stan- 
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dard deviation and coefficient of variation. These summary 
statistics were used to characterize the average levels and 
variability of the hemodynamic values for each person. Mean 
levels of each of these individual means, standard deviations, 
and coefficients of variation were computed over the 12 
subjects in the study. 
The Pearson product-moment correlation coefficient was 
used to evaluate the following associations; the variability in 
PA pressure with cardiac output, the mean level of each he- 
modynamic variable with the standard deviation, the change 
in PA pressure and total pulmonary resistance after drug 
administration with the previously determined coefficient of 
variation for those variables, the hourly changes in cardiac 
output with the mean PA pressure and with the total pul- 
monary resistance. The significance of the effect of drug ad- 
ministration on the PA pressure and the total pulmonary re- 
sistance was evaluated by the t test for paired data. 
Under the assumption that within each subject repeated 
determinations of the hemodynamic variables follow a normal 
distribution, the probability that 2 determinations in the same 
individual differ by more than a certain percent can be ex- 
pressed as a function of the specific percent and the coefficient 
of variation of the distribution of repeat determinations. For 
a given coefficient of variation and percent, this probability 
can be obtained numerically by use of the standard normal 
distribution. Based on the above rationale, we evaluated this 
Patient # 6 FIGURE 1. The hoyr-to-hour changes 
in pulmonary artery (PA) pressure and 
total pulmonary resistance in patient 8 
(A) and in PA pressure and cardiac 
output in patient 6 (B). In patient 8, PA 
pressure increased with essentially no 
change in pulmonary resistance for the 
first 4 hours, at which time PA pressure 
decreased and pulmonary resistance 
increased dramatically. In the last hour 
both PA pressure and pulmonary re- 
sistance increased together. Patient 6 
showed marked variation in PA pres- 
sure from hour to hour, without parallel 
changes in cardiac output. The cardiac 
output increased substantially betlween 
hours 2 and 3 while the PA pressure 
remained essentially unchanged. 
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probability using the average coefficient of variation over 
the 12 subjects as a global estimate of the coefficient of 
variation. 
(Note: In some patients the pulmonary capillary wedge 
pressure could not always be obtained in consecutive hours. 
Consequently, total systemic resistance and total pulmonary 
resistance are being used for statistical analysis in this study. 
In the cases where left and right ventricular filling pressures 
were available, we could not find a difference between the 
amount of variability noted in total systemic resistance and 
systemic vascular resistance, or total pulmonary resistance 
and pulmonary vascular resistance.) 
Results 
Hemodynamic characteristics (Table I): The 
subjects in the study had advanced PPH as evidenced 
by the elevated mean PA pressures (64 f 14 mm Hg) 
and mean total pulmonary resistance (23 f 14 units), 
and reduced cardiac outputs (3.3 f 1.0 liters/min). The 
lowest mean PA pressure of any patient in the study was 
48 mm Hg, and the lowest total pulmonary resistance 
was 13 Wood units. 
Magnitude of spontaneous variability: Hour-to- 
hour changes in the hemodynamic values were recorded. 
The mean levels with the corresponding mean coeffi- 
cients of variation over the 12 subjects are shown in 
Table II. In most cases there were unpredictable swings 
from hour to hour, rather than gradual changes over the 
6-hour period. For example, patient 8 had a mean PA 
pressure rise from 55 to 78 mm Hg, a 42% increase in 1 
hour, and patient 6 had a change in cardiac output from 
2.4 to 5.1 L/min, a 111% increase in 1 hour, without 
apparent cause (Fig. 1). Although the changes in pres- 
sures seen were not necessarily directly proportional to, 
or inversely related to the changes in flow in each case, 
those patients with the greatest variability in their PA 
pressures also had the most variability in their cardiac 
outputs (r = 0.685, p = 0.02) (Fig. 2). 
The distribution of the variability in the patients 






















COEFFICIENT OF VARIATION (%I FOR 
PULMONARY ARTERY PRESSURE 
FIGURE 2. Relation between the amount of variability (coefficient of 
variation) in cardiac output and pulmonary artery pressure. The patients 
with the greatest amount of variability in pulmonary artery pressure also 
manifest the greatest amount of variability in cardiac output as deter- 
mined by hourly measurements. 
TABLE II Hemodynamic Variability Observed over 6 
Consecutive Hours and 95 % Confidence Limits 
for Drug Effect in 1 Patient 
Mean 
Level 
(n = 12) 
Mean CV 








pressure (mm Hg) 
Pulmonary artery 




94f 10 6.7 f 2.4 17 
66f 11 6.6 f 3.1 17 
64% 14 6.4 f 3.6 22 
3.3 f 1.0 10.7 f 5.7 29 






23 f 14 12.9 f 6.9 36 
366 12 12.6 f 6.4 35 
CL = confidence limits; CV = coefficient of variation. 
the coefficient of variation of the PA pressures and the 
pulmonary resistances for each patient are shown in 
Figure 3. The amount. of variability did not appear to 
be skewed because of patients who were obvious outliers 
of the group. 
Relation between variability and severity of the 
disease: We examined whether there was an association 
between the amount of hemodynamic variability and 
the severity of the disease. There was a significant cor- 
relation (p <O.Ol) between the mean value for total 
pulmonary resistance and the standard deviation over 
the g-hour period (r = 0.91), suggesting that patients 































FIGURE 3. The coefficient of variation for total pulmonary resistance 
and mean pulmonary artery pressure for each of the 12 patients in the 
study. These values were distributed fairly evenly in the study group. 
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TABLE III Relation Between the Hourly Measurements in 
Pulmonary Artery Pressure and Pulmonary 
Resistance with the Corresponding Cardiac 
Outout 
Correlation Coefficient (r) 
PI PAP vs CO TPR vs CO 
t 0.33 45 -0.44 85” 
: -0.63 0. 6 -0.94’ 63 
5 0.84 -0.92* 
6 0.23 -0.83” 
i 0.76 84” -0.93” 38 
9 0.27 -0.38 
:: -0.56 70 -0.91’ 2” 
12 0.02 -0.76 
l p <0.05. 
CO, = cardiac outout; PAP = mean pulmonary artery pressure; TPR 
= total pulmonary resistance. 
the most spontaneous hemodynamic variability. This 
was true for the total systemic resistance (r = 0.78) as 
well, but not for any of the other measured variables. 
Relation between: pulmonary blood flow and the 
corresponding pulmonary artery and pulmonary 
resistance: The association between the hourly de- 
terminations of pulmonary blood flow (cardiac output) 
and the corresponding mean PA pressure and total 
pulmonary resistance was analyzed (Table III). A pos- 
itive linear relation between cardiac output and PA 
pressure was found in only 1 patient. However, a linear 
relation was noted between increasing cardiac output 
and a decreasing pulmonary resistance in 7 of the 12 
patients studied. In no patient was an association found 
between an increasing cardiac output and an increasing 
pulmonary resistance. Nonlinear relations were not 
tested. 
Spontaneous variation and drug responsiveness: 
The acute effect of vasodilator administration in the 
patients studied after the 6 hours of baseline measure- 
ments were obtained and analyzed. Hydralazine re- 
sulted in an 8% increase in the mean PA pressure and 
a 16% reduction in pulmonary resistance in the 8 pa- 
tients tested. Neither of these changes was statistically 
significant. Nifedipine resulted in 7% reduction in PA 
pressure and a 25% reduction in pulmonary resistance. 
Both of these changes were significant (Table IV). There 
was no correlation between the change in pulmonary 
resistance or mean PA pressure from administration of 
either nifedipine or hydralazine and the amount 
of variation noted to occur spontaneously in these 
patients. 
Magnitude of change required to be attributed 
to drugs effect: The percentage change in any specific 
hemodynamic variable that would have to be observed 
in order for it to be attributed to a drug effect with 
reasonable confidence, in light of the spontaneous 
variability that was noted, was derived. A table was 
constructed that illustrates the percentage change re- 
quired, based on a 95% confidence level, and the coef- 
ficient of variation as determined from this group of 
patients (Table II). A reduction in mean PA pressure 
of 22% based on 1 control and 1 postdrug determination, 
or a reduction in total pulmonary resistance of 36% is 
required in order to be confident that a vasodilator drug 
was clearly effective in a single patient. When drugs are 
evaluated in groups of patients, however, significant 
drug effects can be determined from parametric testing, 
as it is assumed that the effect of variability within the 
group will cancel itself out. Thus, although individual 
patients tested with nifedipine had changes in PA 
pressure of less than 22%, the drug had a significant 
effect on the group as determined by the Student t 
test. 
Discussion 
The occurrence of spontaneous changes in pulmonary 
resistance in patients with PPH have been described.6 
A previous study of captopril therapy in PPH showed 
how the presence of spontaneous hemodynamic vari- 
ability made the assessment of drug effects difficult.8 
Spontaneous variability is a feature of biologic systems 
and pathologic manifestations of disease,e-11 and its 
quantification is critical in the assessment of drug 
therapies.8J2 
This study confirms that hour-to-hour changes in 
systemic and PA pressure and cardiac output often 
occur in patients with PPH. This variability may be of 
similar magnitude in both the systemic and pulmonary 
circulations, and may be large in some cases. One might 
question whether the variation observed was due to 
technical laxity by the personnel making the measure- 
ments, but if it were, it should have then been ap- 
proximately the same from patient to patient. Patients 
who had the greatest amount of change in their PA 
pressures also had the greatest change in cardiac output, 
which is consistent with biologic behavior. Samet and 
Bernstein13 suggested that a large amount of variability 
in pulmonary resistance is indicative of active and re- 
versible vasoconstriction, and is a feature of less ad- 
vanced disease. However, the amount of variability 
correlated with the level of total pulmonary resistance, 
which suggests that variability is a feature of advanced 
PPH. 
We studied the relation between the changes in pul- 
monary blood flow and the corresponding changes in PA 
pressure and pulmonary resistance to see if we could 
determine the mechanisms of variability. In 1 patient 
the-PA pressure increased with the cardiac output, 
whereas the pulmonary resistance did not, a response 
characteristic of normal subjects. In 7 patients the 
pulmonary resistance fell as pulmonary blood flow in- 
creased, with the changes in PA pressure independent 
of the pulmonary blood flow. This would suggest that 
changes in the cross-sectional area of the pulmonary 
vascular bed were occurring. Whether this was a result 
of changing distensibility in the resistance vessels or of 
vessel recruitment is not known. However, only linear 
relations between flow and pressure, and flow and re- 
sistance were studied and the range of changes in flow 
was narrow. 
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TABLE IV Relation Between Vasodilator Drug Testing and Spontaneous Variability 
Hydraidzine Nifedipine 
PA Pressure Pulmonary Resistance PA Pressure Pulmonary Resistance 
(mm Hg) (units) (mm W (units) 
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C = control value before drug administration; CV = coefficient of variation for the 6-hour baseline determination; NS = not significant; PA = 
pulmonary artery; Rx = value after drug administration; SD = standard deviation. 
It has also been suggested that the presence of 
spontaneous variability in pulmonary vascular resis- 
tance predict success with vasodilators in treating pa- 
tients with pulmonary hypertension.sJ4 We could not 
correlate the amount of variability to drug responsive- 
nesswith nifedipine or hydralazine. Neither were the 
patients with the greatest reduction in pulmonary re- 
sistance from the drugs the same ones that appeared to 
have the most spontaneous change in pulmonary vas- 
cular tone. A modest but significant reduction in PA 
pressure (5 mm Hg) and pulmonary resistance (5 units) 
occurred with nifedipine, but not with hydralazine. 
Bebause the values were measured every hour, the 
possibility exists that a drug response measured at an 
interval of less than 60 minutes may be less influenced 
by spontaneous variability, or that variability may have 
a greater influence in the assessment of chronic therapy 
made over weeks or months. Although these patients 
were randomly referred to us for study, it is also possible 
that variability may not be as evident in other patients 
with pulmonary hypertension, particularly from other 
causes. 
When one reviews previous studies evaluating vaso- 
dilator drugs in PPH, one is impressed by the marked 
lack of uniform criteria that have been used in deciding 
what magnitude of change determines a beneficial drug 
response. Based on the patients in this study, we con- 
structed a table that indicates the amount of change 
required in order to achieve 95% confidence that a he- 
modynamic effect was drug-related. In an individual 
patient there must be a relatively large change (e.g., 2% 
in mean PA pressure and 36% in pulmonary resistance) 
in order for it to be attributed (with 95% confidence) to 
a drug effect rather than spontaneous variability (Table 
II). This must be considered before one makes conclu- 
sions about drug effects in individual patients with 
PPH. 
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